NEW YORK — Abbott said on Friday that it has received Emergency Use Authorization from the US Food and Drug Administration for a PCR-based assay that can detect and differentiate SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus.
The newly authorized Alinity m Resp-4-Plex assay, which is also CE marked, uses a single anterior nasal or nasopharyngeal swab sample collected by a healthcare provider or self-collected at a healthcare facility, according to Abbott. It runs on the company's Alinity m system.